LINCOLN, Neb. (AP) — Nebraska officials say they will receive more than $455,000 in a settlement with two pharmaceutical companies that were accused of overcharging state Medicaid programs.

The settlement announced Wednesday resolves allegations that AstraZeneca Pharmaceuticals, LP and Cephalon, Inc., overcharged for various drugs.

AstraZeneca has paid the states and the federal government $46.5 million, while Cephalon paid $7.5 million. A whistleblower complaint alleged that the companies used accounting techniques to reduce the average manufacturer price reported to the federal government, which resulted in the companies underpaying drug rebates to the states.

The Nebraska attorney general’s office says the state will receive more than $350,000 from AstraZeneca and another $105,000 from Cephalon.